Wednesday, July 8, 2026

Drug profile · INN

avutometinib potassium

avutometinib potassium (AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with Vera Therapeutics. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 6
News articles 0
Congress events 2
Drug details — avutometinib potassium

Quick answer

avutometinib potassium (AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with Vera Therapeutics. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN avutometinib potassium
Brand AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Route ORAL
Formulation CAPSULE, TABLET

Approval history

Authority Status Date
FDA approved

Congress & event coverage

  • Presentation
    ASCO 2026

    1 presentation · oncology

  • Presentation
    ASCO

    1 presentation · oncology

Pipeline programs

  1. Avutometinib Phase 2 · United Therapeutics Europe · Glioblastoma Multiforme (GBM)
  2. REFRaME-P1 Phase 2 · SUTRO BIOPHARMA · Acute Myeloid Leukemia (AML)
  3. BP44382 Phase 1 · HOFFMANN-LA ROCHE · Small Cell Lung Cancer and Neuroendocrine Carcinoma
  4. ION269-CS1 Phase 1 · IONIS PHARMACEUTICALS · Alzheimer’s Disease in Individuals with Down Syndrome
  5. LE 5101 Phase 1 · Pharming Technologies · Activated Phosphoinositide 3-Kinase Delta Syndrome
  6. MB04-A-01-23 Phase 1 · mAbxience · Not applicable, Healthy Volunteers
  1. US 12257288

    Methods of inducing immune tolerance to clotting factors

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12173307

    Methods for the purification of viral vectors

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12059400

    Medical compound

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12030925

    Methods of treating hemophilia A

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 12005220

    Microneedle patch for immunostimulatory drug delivery

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11877989

    Nutritional supplement containing L-α-glycerophosphorylcholine

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11873296

    Solid forms of a dual RAF/MEK inhibitor

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11753461

    Optimized factor VIII genes

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11639527

    Methods for nucleic acid sequencing

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11372008

    Blood factor monitoring assay and uses thereof

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11261437

    Procoagulant compounds

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 11229600

    Compositions and methods for selective GI tract delivery

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 11225650

    Methods of using FIX polypeptides

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 11192944

    Methods of inducing complement activity

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 11091534

    Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10947170

    Process for the preparation of deuterated ethanol from D2O

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10940208

    Nanoassembled complexes of nucleic acids, avidin and biotinylated compounds for use as drug carriers

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10927362

    Processable single chain molecules and polypeptides made using same

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10898554

    Factor IX polypeptides and methods of use thereof

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 10751343

    Nasal compositions stimulating ciliary activity

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is avutometinib potassium?

avutometinib potassium (AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with Vera Therapeutics. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for avutometinib potassium?

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) is a marketed brand name for avutometinib potassium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of avutometinib potassium?

avutometinib potassium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.